Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 11

“Watch and wait” approach in rectal cancer patients following complete clinical response to neoadjuvant chemoradiotherapy does not compromise oncologic outcomes

Pages
951–956
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Those patients in particular who required abdomino-perinealresection before chemoradiation should be informed about this approach if they have achieved complete response clinically.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Although standart treatment for non-metastatic locally advanced rectal cancer includes neoadjuvant chemoradiation followed by surgical resection, patients who have achieved complete clinical response can be followed up without surgery.Materials and Methods: Between 2010 and 2016, 61 patients received neoadjuvant chemoradiotherapy for low rectal cancer.
📊
Key Findings & Data:The 5-year disease free survival was 100%.
💡
Conclusion & Impact:Those patients in particular who required abdomino-perinealresection before chemoradiation should be informed about this approach if they have achieved complete response clinically.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: Although standart treatment for non-metastatic locally advanced rectal cancer includes neoadjuvant chemoradiation followed by surgical resection, patients who have achieved complete clinical response can be followed up without surgery.Materials and Methods: Between 2010 and 2016, 61 patients received neoadjuvant chemoradiotherapy for low rectal cancer. Those patients who achieved clinical complete response were included in the “watch and wait” protocol and did not receive surgery. The remainingpatients underwent radical surgery and some of these were diagnosed as having complete response pathologically. This study comparedthe oncological results of clinically complete responders with those patients defined as pathologically tumor-free.Results: Seven patients who received neoadjuvant chemoradiotherapy were re-staged as having complete clinical response and included in the “watch and wait” approach protocol. The 5-year disease free survival was 100%. Mean follow-up was 63 months and the meanage was 57.3. Fifty-four patients underwent radical surgery and 7 of them were diagnosed as having pathological complete response.The 5-year survival was 100%. Mean follow-up was 56 months and the mean age was 50.6. All patients except one are alive withouttumor recurrence in the surgery group. However, those who received surgery experienced significant morbidities due to their surgery.Conclusion: The oncological results of the “watch and wait” approach patients were no different from the patients who received radicalsurgery and were diagnosed as having pathological complete response. Those patients in particular who required abdomino-perinealresection before chemoradiation should be informed about this approach if they have achieved complete response clinically.

🔖

Cite This Article

NEŞŞAR, G., DEMİRBAĞ, A. E., MISIRLIOĞLU, H. C., SEZER, S. (2019). “Watch and wait” approach in rectal cancer patients following complete clinical response to neoadjuvant chemoradiotherapy does not compromise oncologic outcomes. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 11, 951–956. https://ajindex.com/articles/411298

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Cancer statistics in Turkey. Public Health Institution, Ministry of Health, Ankara 2018
  2. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal management? Dis Colon Rectum 2013; 56: 1109-17. [CrossRef] 3. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012; 99: 897-909. [CrossRef] 4. Weiser MR, Beets-Tan R, Beets G. Management of complete response after chemoradiation in rectal cancer. Surg Oncol Clin N Am 2014; 23: 113-25. [CrossRef] 5. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33. [CrossRef] 6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40. [CrossRef] 7. Callender GG, Das P, Rodriguez-Bigas MA, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 2010; 17: 441-7. [CrossRef] 8. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44. [CrossRef] 9. Garcia-Aguilar J, Shi Q, Thomas CR, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012; 19: 384-91. [CrossRef] 10. Habr-Gama A, Sao Juliao GP, Perez RO. Nonoperative management of rectal cancer: identifying the ideal patients. Hematol Oncol Clin North Am 2015; 29: 135-51. [CrossRef] 11. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-7. [CrossRef] 12. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10: 1319-28. [CrossRef] 13. Neşşar G. Organ preservation in rectal cancer patien